Background: Glial fibrillary acidic protein (GFAP) astrocytopathy, an autoimmune central nervous system disorder with a specific GFAP-IgG, often coexists with other antibodies.
predominantly affects the meninges, brain, spinal cord, and optic nerve. The disease is associated with antibodies against GFAP, and the detection of GFAP-IgG is helpful for diagnosis of GFAP astrocytopathy compared with other inflammatory autoimmune disorders of the CNS (2, 3) .
Overlapping autoimmune syndromes occur commonly in patients with antibody-mediated inflammatory disorders. NMOSD with positive AQP4 antibody often has a concurrent autoimmune disease, such as Sjögren's syndrome, myasthenia gravis, or systemic lupus erythematosus (4, 5) . A few studies have reported that anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis is associated with acute demyelinating encephalomyelitis, myelitis, or NMOSD (6) . Recently, a Mayo clinic study (3) found that GFAP-IgG was accompanied by coexisting NMDA-R-IgG, AQP4-IgG, or both. Therefore, coexistence of autoantibodies in GFAP astrocytopathy is not rare.
However, GFAP astrocytopathy is poorly understood, and only limited reports have described the overlapping syndromes. In our previous studies (7, 8) , we described a group of patients with GFAP astrocytopathy. In this study, we have recruited additional patients with GFAP astrocytopathy, of whom 10 had overlapping syndromes, and focused on the clinical data, magnetic resonance imaging (MRI) features, and cerebral spinal fluid (CSF) examination.
PaTienTs anD MeThODs

Patients
This retrospective study was approved by the Ethics Committee of the Second Affiliated Hospital of Guangzhou Medical University, China. Data analysis was performed based on the Chinese laws for data protection. All patients provided written informed consent.
From June 2013 to September 2017, paired samples of serum and CSF were prepared for study as described in the previous study (8) . For this study, serum and CSF samples from 749 Chinese patients with inflammatory and non-inflammatory symptoms were collected and routinely tested for autoantibodies. All samples were collected during the early active disease stage, prior to treatment. No healthy controls were included in our study, because of a lack of CSF samples for these individuals.
We detected positive GFAP antibody in 30 patients. None of these patients had a history of neoplasm. The 28 control patients (female/male, 27/1; median age of onset, 41 years) with positive AQP4 antibody were diagnosed as NMOSD according to published criteria (9) and were negative for GFAP antibody. Data acquired from the first admission record included age, sex, medication, MRI features, and clinical characteristics.
anti-gFaP antibody Detection in csF and serum
Tissue-based and cell-based assays were used, as described in our previous study (8) . Antibody detection was performed using an indirect immunofluorescence assay on rat hippocampal and cerebellar tissue. Samples were retested in a cell-based assay using HEK293 cells transfected with GFAPα and GFAPε genes.
Testing of Other antibodies
The presence of AQP4-M1, AQP4-M23, myelin oligodendrocyte glycoprotein (MOG), collapsin response mediator protein 5, Hu, Yo, Ri, amphiphysin, Ma2, NMDAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor 1, AMPA2, leucine-rich glioma-inactivated 1, γ-aminobutyric acid type-A receptor, and glutamic acid decarboxylase 65 antibodies was assessed in patients with GFAP antibodies. Detection was carried out as described in previous studies (7, 8) .
statistical analysis
All statistical analyses were performed using the Statistical Program for Social Sciences software (version 17.0; SPSS, Inc., Chicago, IL, USA). Statistical analyses were performed with the Fisher's exact test for binary and categorical data. The MannWhitney test was used for continuous variables, and p < 0.05 was considered statistically significant.
resUlTs
Patient Demographics and clinical Data
A total of 30 patients positive for GFAP antibodies and with detailed data were included in this retrospective study. This cohort comprised 21 females and 9 males (a female to male ratio of 2.33). Their median age at onset was 46 years (range, 19-77 years), of whom eight patients (26.7%) were older than 60 years at disease onset.
Among these 30 participants, 10 patients (33.3%) with other specific antibodies were described as overlapping syndrome in this study ( Table 1 ). Of them, four patients were positive for AQP4 antibody, two were positive for NMDAR antibody, three patients had an unknown neuronal antibody, and one patient was positive for both AQP4 and MOG antibodies ( Table 1 ). The patients who had three different kinds of antibody (GFAP, AQP4, and MOG) underwent brain pathological examination (Figure 1) . The pathological examination showed extensive inflammatory cells, including CD20
+ , CD3 + , and CD138 + cells, around the vessels. Immunohistochemical analysis also showed complete loss AQP4 and GFAP. However, MOG expression was preserved, and no obvious demyelination could be found in this patient. Anti-GFAP antibody and other specific antibodies that occurred simultaneously at the initial attack were found in eight patients. One patient developed GFAP astrocytopathy following NMO (10 years later), and another patient developed GFAP astrocytopathy following NMDAR encephalitis (1 year later; Figure 2 ).
The patients with overlapping syndrome included six females and four males, whose median age at onset was 31 years (19-57 years). The main brain symptoms observed included fever (n = 5), headache (n = 5), ataxia (n = 1), psychosis (n = 5), hypersomnia (n = 3), dyskinesia (n = 1), dementia (n = 4), seizure (n = 3), myelitis (n = 6), and optical symptoms (n = 6). CSF abnormalities were found in nine patients. They all received brain MRI scans, and eight of these patients showed brain abnormalities (80%). Brain MRI in four patients (40%) revealed characteristic radial enhancing patterns in the white matter around the ventricle. Cortical abnormalities were found in four patients (40%) by MRI. Other brain abnormalities occurred in the hypothalamus (4, 40%), midbrain (4, 40%), pons (2, 20%), medulla (2, 20%), cerebellum (2, 20%), and meninges (2, 20%). Six of these patients (60%) exhibited lesions in the spinal cord, of whom two patients had very long lesions from the cervical segment to lumbar segment of spinal cord.
comparison of gFaP astrocytopathy and aQP4 astrocytopathy Phenotypes at Onset
According to their overlapping status, 30 patients with positive GFAP antibody were divided into 2 subgroups: overlapping syndrome (n = 10) and non-overlapping syndrome (n = 20). In the GFAP astrocytopathy subgroup study, patients with overlapping syndrome were younger at onset than those with nonoverlapping syndrome (median age, 52 vs 31 years, p = 0.0046). However, no further differences could be confirmed between the two subgroups. To compare the difference between GFAP astrocytopathy and AQP4 astrocytopathy, 28 patients with positive AQP4 antibody who had initial data and were negative for GFAP antibody were recruited as controls. The GFAP astrocytopathy group had fewer females than the AQP4 astrocytopathy group (female/male, 21/9 vs 27/1, p = 0.012), more fever (56.7 vs 3.6%, p = 0. Table 2 .
DiscUssiOn
In previous Mayo clinic reports (2, 3) , Lennon and her colleagues identified patients with GFAP astrocytopathy with several additional kinds of autoantibody, including NMDAR antibody, AQP4 antibody, and MOG antibody, which suggests an immune encephalitis or demyelinating disorder. They found that 41 patients had one or more coexisting antibodies in serum or CSF (40%), of which NMDAR-IgG was the most common coexisting antibody, and AQP4-IgG was the next most common. In this study, we found that 10 of 30 patients (33.3%) had a coexisting antibody, supporting the finding that coexisting antibodies are common in patients with GFAP astrocytopathy. In addition to the two patients with NMDAR antibody, it is interesting that we also found three patients with an unknown neuronal antibody.
Other antibodies such as AQP4 or MOG, in association with GFAP antibodies, were found in another five patients, which was similar to the above study (3) . Although both GFAP and AQP4 astrocytopathy have specific IgGs targeting astrocytes and are involved in myelitis, optic neuritis, and brain symptoms, it seems that GFAP astrocytopathy is quite different from AQP4 astrocytopathy in many clinical manifestations, including fever, headache, and psychiatric symptoms, suggesting immune encephalitis features (2, 3) . Furthermore, our results also showed that obvious findings were different in initial MRI patterns between GFAP and AQP4 astrocytopathy. In patients with GFAP astrocytopathy, almost half of the patients with lesions had the radial enhancement pattern. By contrast, only one patient with AQP4 astrocytopathy had such enhancement. A striking pattern of linear perivascular radial gadolinium enhancement in 53% of patients was described in a recent study (3) , similar to our present results. In the two subgroups of GFAP astrocytopathy, similar differences could be seen between the subgroups and AQP4 astrocytopathy. Therefore, our data indicate that different immune mechanisms were shared in GFAP and AQP4 astrocytopathy. However, although two or more immune mechanisms may occur in GFAP astrocytopathy with overlapping syndrome, no further differences could be identified between the patients with and without overlapping syndrome, except for the age at onset. Therefore, the exact difference between the two kinds of patients with GFAP astrocytopathy is unknown. However, we only had 10 patients with overlapping syndrome, which represents a very small sample size, and future studies should be undertaken in a larger population.
This study provides some interesting findings and issues that are important for clinical diagnosis and recognition. In our 10 patients with overlapping syndrome, 2 cases developed GFAP astrocytopathy separated in time from the episode of anti-NMDAR encephalitis or AQP4 astrocytopathy, making it easy to recognize and draw a definite diagnosis. However, there were eight patients with GFAP antibodies occurring simultaneously with clinical and MRI features of autoimmune encephalitis or demyelinating disorders. This could be a confounding condition for clinicians at the initial episode. Based on the clinical manifestations and positive AQP4-IgG, five patients could be diagnosed as NMOSD. The patient with three kinds of antibodies who underwent pathological examination and showed typical extensive AQP4 loss also met the pathological criterion of positive anti-AQP4 NMOSD. The other three patients could be diagnosed as autoimmune encephalitis, according to the diagnostic criteria (10) and positive neuronal antibody. These mixed phenotypes suggest the coexistence of two simultaneously active immune mechanisms, which has been described in NMDAR encephalitis with AQP4 or MOG antibodies (5) . Therefore, as overlapping antibodies occur simultaneously at onset in patients with autoimmune encephalitis or demyelinating disorders, suitable diagnosis and classification is a clinical challenge. Diagnostic criteria for GFAP astrocytopathy should be designed in the future.
In conclusion, we found that 10 of 30 patients with GFAP-IgG harbor additional antibodies. Therefore, overlapping autoantibodies are common in GFAP astrocytopathy, involving AQP4-IgG, MOG-IgG, NMDAR-IgG, or other neuronal antibodies. In this study with small sample numbers, our results suggest that there is no critical difference between patients with and without overlapping syndrome.
eThics sTaTeMenT
This retrospective study was approved by the Ethics Committee of the Second Affiliated Hospital of Guangzhou Medical University, China. Data analysis was performed based on the Chinese laws for data protection.
